tipifarnib has been researched along with tamoxifen in 4 studies
Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (tamoxifen) | Trials (tamoxifen) | Recent Studies (post-2010) (tamoxifen) |
---|---|---|---|---|---|
309 | 92 | 94 | 20,630 | 2,227 | 6,256 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Balis, FM; Chow, C; Clark, G; Eng-Wong, J; Gantz, SB; Jayaprakash, N; Lebowitz, PF; Venzon, D; Widemann, BC; Zujewski, J | 1 |
Dalenc, F; Favre, G; Faye, JC; Giamarchi, C; Petit, M; Poirot, M | 1 |
Detre, S; Dowsett, M; Head, JE; Howes, A; Johnston, SR; Kaye, S; Martin, LA; Pancholi, S; Quinn, E; Salter, J | 1 |
Allal, BC; Chaoui, K; Dalenc, F; Doisneau-Sixou, SF; Favre, G; Filleron, T; Lauwers-Cances, V; Malissein, E; Marsili, S; Meunier, E; Monsarrat, B; Renée, N; Roché, H; Schiltz, O | 1 |
2 trial(s) available for tipifarnib and tamoxifen
Article | Year |
---|---|
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Exanthema; Farnesyltranstransferase; Fatigue; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Tamoxifen; Treatment Outcome | 2005 |
Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Farnesyltranstransferase; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Protein Array Analysis; Quinolones; Tamoxifen | 2010 |
2 other study(ies) available for tipifarnib and tamoxifen
Article | Year |
---|---|
Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Female; Humans; Pyrrolidines; Quinolones; Receptors, Estrogen; Tamoxifen | 2005 |
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Drug Therapy, Combination; Farnesyltranstransferase; Female; Flow Cytometry; Fluorescent Antibody Technique; G1 Phase; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Quinolones; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transplantation, Heterologous | 2007 |